Devyser Diagnostics AB (FRA:OL0) ROCE %: 5.12% (As of Mar. 2026)


FRA:OL0 Devyser Diagnostics AB FRA:OL0
77 GF Score
Price €7.59
GF Value €14.06
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Devyser Diagnostics AB ROCE %?

Devyser Diagnostics AB FRA:OL0 77 ROCE % is 5.12% as of Mar. 2026. GuruFocus rates FRA:OL0 with a GF Score™ of 77/100 and a GF Value™ of €14.06 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Devyser Diagnostics AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.12%.

Devyser Diagnostics AB  (FRA:OL0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Devyser Diagnostics AB ROCE % Related Terms

Devyser Diagnostics AB ROCE % Historical Data

* Premium members only.

The historical data trend for Devyser Diagnostics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devyser Diagnostics AB ROCE % Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -8.84 -11.51 -11.85 -12.57 0.10

Devyser Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.12 5.94 1.45 18.55 5.12
FRA:OL0
77GF Score
Devyser Diagnostics AB FRA:OL0
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devyser Diagnostics AB ROCE % Calculation

Devyser Diagnostics AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.037/( ( (41.191 - 6.312) + (43.162 - 6.515) )/ 2 )
=0.037/( (34.879+36.647)/ 2 )
=0.037/35.763
=0.10 %

Devyser Diagnostics AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1.892/( ( (43.162 - 6.515) + (43.644 - 6.369) )/ 2 )
=1.892/( ( 36.647 + 37.275 )/ 2 )
=1.892/36.961
=5.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.12% mean?
Devyser Diagnostics AB (FRA:OL0) has a ROCE % of 5.12% as of Mar. 2026.
Is Devyser Diagnostics AB's ROCE % too high?
Devyser Diagnostics AB's current ROCE % is 5.12%. The Medical Devices & Instruments industry median ROCE % is 2.23. Devyser Diagnostics AB's value of 5.12% is 129.6% above this industry median. Overall, Devyser Diagnostics AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Devyser Diagnostics AB's ROCE % compare to ABT and SYK?
Devyser Diagnostics AB's ROCE % of 5.12% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Devyser Diagnostics AB's value of 5.12% is 129.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devyser Diagnostics AB's current ROCE % of 5.12% is 129.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devyser Diagnostics AB's current ROCE % is 5.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devyser Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Devyser Diagnostics AB (FRA:OL0) is currently considered Significantly Undervalued. The stock's GF Value™ is €14.06, compared to a current price of €7.59 — trading 46% below its estimated fair value. The current ROCE % is 5.12% and 129.6% above the Medical Devices & Instruments industry median of 2.23. Devyser Diagnostics AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Devyser Diagnostics AB (FRA:OL0), the current ROCE % is 5.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devyser Diagnostics AB (FRA:OL0) Overvalued in 2026?

Based on GuruFocus' analysis, Devyser Diagnostics AB stock appears to be undervalued. The current stock price of €7.59 is trading 46% below its estimated GF Value™ of €14.06. GuruFocus considers Devyser Diagnostics AB to be Significantly Undervalued.

Key valuation signals for FRA:OL0:

  • ROCE %: 5.12%
  • GF Value™: €14.06 vs. price of €7.59 (46% below fair value)
  • GF Score™: 77/100 with 2 warning signs
  • Industry Position: 129.6% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:OL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devyser Diagnostics AB Business Description

Other Exchanges DVYSR:Sweden
Address Branningevagen 12, Arsta, SWE, 120 54
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
77GF Score

Get the complete analysis for FRA:OL0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.59
Price
€14.06
GF Value